Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry
May 10
Have your own idea? Try our Stock Screener
U.K. (FTSE) Biotech Industry Analysis
UpdatedMay 25, 2025
DataAggregated Company Financials
Companies22
- 7D-1.3%
- 3M-0.8%
- 1Y-15.4%
- YTDn/a
Over the last 7 days, the Biotech industry has dropped 1.3%, driven by Genus declining 3.1%. In contrast, Faron Pharmaceuticals Oy has gained 9.3%. The industry has fallen 15% in the last year. Looking forward, earnings are forecast to grow by 33% annually.
Industry Valuation and Performance
Has the U.K. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 26 May 2025 | UK£2.4b | UK£879.0m | -UK£92,157,633.95 | 13.8x | -26.2x | 2.7x |
| Wed, 23 Apr 2025 | UK£2.1b | UK£876.5m | -UK£170,948,298.30 | 16.6x | -12.4x | 2.4x |
| Fri, 21 Mar 2025 | UK£2.4b | UK£844.0m | -UK£277,143,424.75 | 16.9x | -8.7x | 2.9x |
| Sun, 16 Feb 2025 | UK£2.7b | UK£841.7m | -UK£294,450,173.91 | 86.9x | -9.2x | 3.2x |
| Tue, 14 Jan 2025 | UK£2.5b | UK£842.8m | -UK£297,311,300.79 | 71.6x | -8.4x | 3x |
| Thu, 12 Dec 2024 | UK£2.7b | UK£841.3m | -UK£293,157,899.89 | 79.9x | -9.1x | 3.2x |
| Sat, 09 Nov 2024 | UK£2.8b | UK£840.3m | -UK£292,669,951.14 | 89.3x | -9.4x | 3.3x |
| Mon, 07 Oct 2024 | UK£2.9b | UK£840.1m | -UK£295,236,161.83 | 97.5x | -9.9x | 3.5x |
| Wed, 04 Sep 2024 | UK£2.8b | UK£834.9m | -UK£289,017,668.26 | 30.6x | -9.8x | 3.4x |
| Fri, 02 Aug 2024 | UK£2.7b | UK£838.3m | -UK£257,806,790.96 | 31.2x | -10.5x | 3.2x |
| Sun, 30 Jun 2024 | UK£2.5b | UK£835.8m | -UK£261,129,045.99 | 29.4x | -9.5x | 3x |
| Tue, 28 May 2024 | UK£3.0b | UK£836.7m | -UK£287,424,883.92 | 31.1x | -10.4x | 3.6x |
| Thu, 25 Apr 2024 | UK£3.1b | UK£902.8m | -UK£201,599,900.90 | 30x | -15.1x | 3.4x |
| Sat, 23 Mar 2024 | UK£3.1b | UK£900.2m | -UK£203,946,855.16 | 34.5x | -15.4x | 3.5x |
| Mon, 19 Feb 2024 | UK£3.1b | UK£913.4m | -UK£198,085,887.55 | 31.2x | -15.8x | 3.4x |
| Wed, 17 Jan 2024 | UK£6.4b | UK£1.3b | -UK£245,592,050.00 | 38.3x | -26x | 5x |
| Fri, 15 Dec 2023 | UK£6.2b | UK£1.3b | -UK£245,035,687.00 | 37.1x | -25.1x | 4.9x |
| Sun, 12 Nov 2023 | UK£6.3b | UK£1.3b | -UK£243,279,195.00 | 37.1x | -25.9x | 5x |
| Tue, 10 Oct 2023 | UK£6.5b | UK£1.3b | -UK£250,845,593.00 | 37.6x | -26.1x | 5.1x |
| Thu, 07 Sep 2023 | UK£6.6b | UK£1.3b | -UK£205,725,417.00 | 23.6x | -32x | 5.2x |
| Sat, 05 Aug 2023 | UK£6.9b | UK£1.3b | -UK£209,009,826.00 | 23.6x | -32.8x | 5.4x |
| Mon, 03 Jul 2023 | UK£6.7b | UK£1.3b | -UK£209,123,429.00 | 23.9x | -31.9x | 5.3x |
| Wed, 31 May 2023 | UK£7.0b | UK£1.3b | -UK£204,828,428.00 | 23.1x | -34x | 5.5x |
| Fri, 28 Apr 2023 | UK£7.1b | UK£1.3b | -UK£186,155,718.00 | 23.6x | -38x | 5.6x |
| Sun, 26 Mar 2023 | UK£7.2b | UK£1.2b | -UK£155,777,625.00 | 25.3x | -46.3x | 5.8x |
| Tue, 21 Feb 2023 | UK£7.4b | UK£1.2b | -UK£150,025,949.00 | 27.2x | -49.5x | 6.3x |
| Thu, 19 Jan 2023 | UK£7.8b | UK£1.2b | -UK£140,268,791.00 | 27.8x | -55.3x | 6.7x |
| Sat, 17 Dec 2022 | UK£7.4b | UK£1.2b | -UK£137,949,903.00 | 25.6x | -53.7x | 6.4x |
| Mon, 14 Nov 2022 | UK£7.9b | UK£1.2b | -UK£140,723,058.00 | 24.1x | -56.1x | 6.8x |
| Wed, 12 Oct 2022 | UK£6.9b | UK£1.2b | -UK£150,996,046.00 | 26.4x | -45.4x | 5.9x |
| Fri, 09 Sep 2022 | UK£7.3b | UK£1.1b | -UK£148,681,430.00 | 36.9x | -49.2x | 6.5x |
| Sun, 07 Aug 2022 | UK£7.3b | UK£1.1b | -UK£201,439,580.00 | 37.6x | -36.4x | 6.6x |
| Tue, 05 Jul 2022 | UK£6.9b | UK£1.1b | -UK£174,917,505.00 | 35.9x | -39.3x | 6.2x |
| Thu, 02 Jun 2022 | UK£7.1b | UK£1.1b | -UK£153,008,288.00 | 37.9x | -46.7x | 6.4x |
Price to Earnings Ratio
-46.7x
Current Industry PE
- Investors are pessimistic on the British Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 5.2x is higher than the industry's current PS ratio of 2.7x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 7.5% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Comparison
How does U.K. Biotech compare with similar industries?
| GB Market | 0.24% | |
| Healthcare | 1.26% | |
| Biotech | -1.33% | |
| Biotech | -1.33% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| FARN Faron Pharmaceuticals Oy | UK£2.35 | 9.3% +UK£24.9m | 22.1% | PE-13.5x | |
| OXB Oxford Biomedica | UK£3.20 | 6.0% +UK£19.1m | -2.1% | PS2.6x | |
| PRTC PureTech Health | UK£1.35 | 3.2% +UK£10.1m | -40.7% | PE8.2x | |
| BVXP Bioventix | UK£29.00 | 5.5% +UK£7.8m | -32.6% | PE19.3x | |
| SCLP Scancell Holdings | UK£0.099 | 7.0% +UK£6.7m | -2.0% | PE-6.4x |
